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Introduction: The cost-utility of vagus nerve stimulator (VNS) devices for medically refractory epilepsy has yet to be estimated.
Methods: Using a meta-analysis of randomised controlled trials of VNS, we estimate that six people require implantation in
order for one person to experience a 50% reduction in seizure frequency. Costs averted from improved epilepsy control were
ascertained from published literature. Values for health states were obtained from a series of 42 seizure clinic attenders using
time trade-off techniques and the EQ-5D health status instrument. The cost per quality adjusted life year gained was estimated
and the values obtained were tested in a sensitivity analysis.
Results: Improved epilepsy control averted, on average, £745 health care costs per annum. People with epilepsy had great
difficulty performing the time trade-off experiment, but those who managed to complete the task valued a 50% reduction in
their own seizure frequency at 0.285 units. For a programme of six implants, the baseline model estimated the cost per quality
adjusted life year gained at £28 849. The most favourable estimate was equal to £4785 per quality adjusted life year gained,
assuming that the number needed to treat was similar to published series in which one response was obtained for every three
implants. The least favourable estimate was equal to £63 000 per quality adjusted life year gained, when EQ-5D utility values
were used. The cost per quality adjusted life year gained was not sensitive to changes in length of stay, nor complication rates,
but was significantly influenced by cost of device and device battery life expectancy.
Conclusion: There is not a strong economic argument against a programme of VNS implantation, although care should be taken
to try and identify and treat those most likely to benefit.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
There is now evidence to support the use of vagus
nerve stimulator (VNS) devices for medically refrac-
tory epilepsy1. However, these devices cost about
£5500 to purchase and little is known about their rel-
ative costs and benefits. In chronic disorders, such as
epilepsy, health care staff are being asked to assess
the relative costs and benefits of new and existing
interventions. Local funding decisions may await an
estimate of the relative costs and benefits of treatment,
as resources for healthcare are finite2. Many epilepsy
specialists, particularly in the United Kingdom have
had difficulty obtaining funds for vagus nerve stim-
ulation programmes, as there have been no original
economic evaluations to date.
Recently the American Academy of Neurology3
stated that:
. . . Vagus nerve stimulator devices and implanta-
tion surgery are costly. This modality would be
cost-effective only if studies could show decreased
doctor and emergency visits, reduced dependence
upon anti-epileptic drugs, and improved quality
of life. Such an outcome analysis remains to be
done.
We report an economic evaluation of vagus nerve
stimulators for the treatment of medically refractory
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Fig. 1: Meta-analysis of randomised controlled trials of high versus low frequency vagus nerve stimulation.
epilepsy, using health state valuations of people with
epilepsy.
METHODS
The cost per quality adjusted life year gained is equal
to the net costs from a programme of implantation suf-
ficiently large to benefit at least one person, divided by
the net gain in quality adjusted life years. Methods are
described to (i) estimate the efficacy of VNS devices;
(ii) calculate costs of implantation; (iii) estimate costs
averted from improved epilepsy control; and (iv) esti-
mate the number of quality adjusted life year gained
by valuing the health gained from improved epilepsy
control.
Efficacy of vagus nerve stimulator devices
We derived an overall estimate of the efficacy of VNS
devices from meta-analysis of published trials. We
identified two randomised controlled trials4, 5 from a
search of MEDLINE, EMBASE, The Cochrane Con-
trolled Trials Register and hand search of abstracts
from a satellite symposium on the use of VNS6. We
estimated that for every six (95% CI 3–14) people
implanted and stimulated at high frequency that there
would be at least one person with a 50% or greater
reduction in seizure frequency (Fig. 1).
Costs of epilepsy
We identified seven cost of epilepsy studies7–13 from
356 abstracts located by a MEDLINE and EMBASE
search using the terms ‘cost’ and ‘epilepsy’. Costs
were inflated or deflated to UK 1996 prices using the
UK Retail Price Index. Prices from other countries
were inflated or deflated to 1996 US prices using the
Bureau of Labour Statistics Consumer Price Index.
Purchasing Power Parity calculations were used to
convert the value of US goods and services to UK val-
ues, where US$1.00 purchased £0.641 of UK goods
and services in 199614. From these studies we esti-
mated that a reduction in seizure frequency equivalent
to the impact of a successful VNS implantation would
avert £745 of healthcare costs (Table 1). One study
which specifically described the costs averted from a
programme of VNS implantation, and estimated that
£2958 of costs were averted per year of successful
VNS implantation13. As our pre-specified methods
had stated that we would take a mean cost across all
studies, we present a baseline estimate using the mean
costs from all studies, and used data from the single
study which specifically examined VNS costs in our
sensitivity analysis.
Cost of VNS implantation
We obtained costs for theatre usage, and in-patient
stay from the Scottish Healthcare Purchasing Informa-
tion Centre, based at Ninewells Hospital and Medical
School. The cost of a VNS device was £5500.
Quality adjusted life years gained
A literature search using MEDLINE and EMBASE
identified a single study which computed utility val-
ues for an appropriate population of people with
epilepsy15. That study used a time trade-off method16
to value health states of people with epilepsy (Table 2).
Using this data, a VNS candidate could have a base-
line utility of either 0.40 or 0.66, and if successfully
treated with a VNS device, could increase their utility
value to 0.79 (Table 2—50% reduction in seizure fre-
quency). Accordingly, values of quality adjusted life
years gained of 0.13 or 0.39 per year of successful
treatment could be derived. We sought to reproduce
these values in a population of 42 people with medi-
cally refractory epilepsy attending the Epilepsy Clinic
at Ninewells Hospital and Medical School, Dundee.
We obtained Ethics Committee approval and partic-











Table 1: Costs averted by improved seizure control.
Author (study size and price base year) Definition of active epilepsy Definition of less active epilepsy Annual cost per person
with active epilepsy
(1996 £)
Cost per person per
annum less active
epilepsy (1996 £)
Additional cost per year
of less active epilepsy
(1996 £)
van Hout et al.7 (N = 300, US$ 1993) >1 per day <1 seizure per day, >1 seizure
per week
2856 1860 997
Jacoby et al.8 (N = 789, UK£ 1993) >1 seizure per month <1 seizure per month 1655 895 760
Cockerell et al.9 (N = 1682, UK£ 1994/1989) ≥1 seizure in last 24 months Seizure free in last 24 months 567 89 478
Begley et al.10 (US$ 1990) Non-institutionalised with
frequent seizures
Persistent but rare seizures (26064) (lifetime cost) (10312) (lifetime cost) (15752) (lifetime cost)
Selai et al.11 (N = 47, UK£ 1997) Pre-TPX Successful treatment with TPX
(includes 50% reduction in
seizure frequency)
0 1494 −1494
Selai et al.11 (N = 26, UK£ 1997) Pre-LMT Successful treatment with LMT
(includes 50% reduction in
seizure frequency)
0 1822 −1822
Malmgren et al.12 (N = 52, US$ 1991) Median 12 seizures per month ≥50% reduction in seizure
frequency
1177 1023 154
Boon et al.13 (N = 15, US$ 1995–1998) 26 seizures per month 11 seizures per month 5660 2702 2958
Summary of eight published studies. LMT, lamotrigine; TPX, topiramate; VGB, vigabatrin.
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Table 2: Utility values from a study of Lamotrigine add-on
therapy for epilepsy, Messori et al.15.
Epilepsy severity N Mean utility SD Range
Level 1 9 0.40 0.07 0.32–0.50
Level 2 12 0.66 0.08 0.56–0.78
Level 3 30 0.79 0.13 0.51–1.00
Level 4 15 0.91 0.09 0.74–1.00
Level 5 15 0.96 0.04 0.88–1.00
All 81 0.78 0.19 0.32–1.00
Level 1: non-responder, withdrawal of LMT due to toxicity.
Level 2: no response. Level 3: at least 50% reduction in seizure
frequency >1 seizure per month. Level 4, at least 50% reduction
<1 seizure per month. Level 5 seizure free.
Liverpool Epilepsy Battery17, the EQ-5D Health Sta-
tus Instrument18, and a time trade-off experiment16 for
their own health state and a hypothetical health state in
which their seizure frequency is reduced by 50%. The
utility values were used to estimate quality adjusted
life years gained from successful epilepsy treatment
with a VNS. We used to social tariff for the EQ-5D
Health Status Instrument to derive utility values19.
Cost-utility analysis
The cost per quality adjusted life year gained is equal
to the net cost divided by the total number of quality
adjusted life years gained. The net cost is equal to the
total cost of an implantation programme minus the
costs averted. The values used in baseline cost-utility
models are summarised (Table 3).
Other model assumptions
We assumed that the life expectancy of a device bat-
tery was 5 years, which means that after this period of
time a further procedure (as a day case ) is required
Table 3: Baseline inputs for calculation of cost per quality adjusted life year gained from VNS implantation.
Input Value Comment
Number needed to treat 6 (95% CI 3–14) From meta-analysis
Cost per implant £5500 Values from local neuroscience directorate. Used value of
£5000 for sensitivity analysis
Cost per day of in-patient stay £315 From Scottish Healthcare Purchasing Information Centre
Length of in-patient stay 3 days Range 1–3 days for sensitivity analysis
Cost per hour of theatre time £395 Assume 1.5 hours theatre time per implant
Cost per infected device £3100 Cost of 7 days as inpatient receiving IV antibiotics plus
explant procedure. (Scottish Healthcare Purchasing
Information Centre)
Quality adjusted life years gained
per implant
0.285 Values from seven valid time trade-off values. Used range
0.13–0.39 (Messori et al.15) and 0.167 (EQ-5D values19)
for sensitivity analysis
Life expectancy of implant battery 5 years Range 4–6 years for sensitivity analysis
to maintain the device. The model was therefore re-
stricted to a 5 year time horizon, which is a reasonable
assumption as a longer time horizon implies that no
other effective therapy is likely to emerge during that
time. We also examined the published literature to de-
termine a device removal rate of 2.7% and an infection
risk of 1.1%, each requiring in-patient treatment. We
assumed that an infected device would require 7 days
in-patient treatment with intravenous antibiotics and
would eventually require removal. Future costs were
discounted at a rate of 6% (UK Government Treasury
Rate), and future health gains (quality adjusted life
years) were discounted at a rate of 2%. Discounting
is a way of taking into account the fact that people
generally prefer, and therefore place greater value on,
goods that are immediately available than those avail-
able at a point in the future20, 21.
Sensitivity analysis
A sensitivity analysis22 was performed to assess the
impact of changes in model assumptions on the final
cost per quality adjusted life year gained.
RESULTS
Quality adjusted life years gained
In our own population we found that people with
epilepsy found the time trade-off very difficult to ac-
complish and out of 43 consented participants, 42 gave
responses to some or all the questions. Time trade-off
experiments were extremely difficult for the patient
population. Six people were unable to give any an-
swer. Thirty people either did not wish to trade any
time at all or traded an infinitesimally small amount of
time, i.e. seconds or minutes out of a 20 year period.











Table 4: Sensitivity analysis: seven selected models for the cost per quality adjusted life year gained from vagus nerve stimulation (values as per baseline unless otherwise stated).
Baseline Daycase Costs averted from Costs averted from EQ-5D health state Messori health state Messori health state 10% complication Targeted to most
implantation VNS cost study VNS study and valuations19 valuation 1 (Table 2) valuation 2 (Table 2) rate likely responders
(Boon et al.13) daycase surgery
Number needed to treat 6 3
Cost per VNS device £5500
Length of hospitalisation 3 days 1 day 1 day
Cost of devices plus surgical
procedures
£39465 £34725 £34725 £39776
Costs averted £745 per annum of
successful treatment
£2958 £2958 £2958
Quality adjusted life years gained
per successful device
0.285 0.167 0.130 0.390
Cost per quality adjusted life year
gained
£28849 £25384 £20599 £17134 £49233 £63245 £21082 £29076 £4785
Change from baseline cost per
quality adjusted life year gained
Baseline −12% −29% −41% +71% +119% −27% +1% −83%
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other responses made it clear that they did have signif-
icant health problems at the time of interview. Of the
remaining 37 participants, only 7 appeared to trade in
a manner described in the health state valuation lit-
erature. These seven people valued a 50% reduction
in seizure frequency with a utility value of 0.285. Us-
ing the EQ-5D quality of life instrument people with
a seizure frequency of less than one per month had a
mean utility of 0.848 (n = 17) compared to a mean
utility value of 0.681 for those with a seizure frequency
of greater than 1 per month (n = 25). For a 50% re-
duction in seizure frequency, the mean gain in health
could reasonably be valued as 0.167 quality adjusted
life years.
Using these utility values, and estimates for the costs
incurred and costs averted (Table 3) we estimate that
the baseline cost per quality adjusted life year gained
from a programme of six VNS implants, each with a
battery life of 5 years, gaining 0.285 quality adjusted
life years per annum, and averting £745 of health care
costs to be £28 950 (1996 prices). Using the 95% con-
fidence intervals (CI) for the number needed to treat,
the range of possible values has to lie between £13 000
and £71 000 per quality adjusted life year gained.
Sensitivity analysis
Clearly there are many potential permutations for this
economic model. However, we present seven reason-
able alternatives to explore the effect of changes to
important variables or examine the effect of different
neurological or neurosurgical practice (Table 4).
The range of values from sensitivity analysis was
between £4785 for a model which assumed that the
device could be targeted to those with a 33% chance
of response to £63 245 per quality adjusted life year
gained when unfavourable values for health gains were
used (Table 4). If we decreased the life expectancy
of the device to 4 years, the baseline cost per quality
adjusted life year gained rose sharply to £36 161, but
a small increase in the life expectancy of the device
to 6 years caused a 17% fall in the value to £24 000
per quality adjusted life year gained (Table 4). If the
device cost fell by 10% to £5000, the cost per quality
adjusted life year gained would be, all other things
being equal, £26 656 (Table 4).
DISCUSSION
Our model suggests that the economic argument
against VNS implantation (with a 1 in 6 response rate)
is weak, particularly given the clinical imperative to
treat in an otherwise no win situation of medically
intractable epilepsy. As VNS is a last resort treat-
ment, with a good chance of a meaningful reduction
in seizure frequency, a case can be made for adopting
the new technology.
The cost per quality adjusted life year gained from
our model is probably an overestimate as we have
failed to capture important health benefits such as
those of carers. Our baseline value of 0.285 quality ad-
justed life years gained per year of successful epilepsy
treatment may also be an underestimate. Messori et
al.15 imply that a good responder could gain up to
0.39 quality adjusted life years per year of successful
stimulation (Table 2), and in such a case the cost per
QALY gained would be close to £20 000. Follow-up
studies of VNS patients have shown trends towards
improvements in seizure control over time23. While
this observation needs confirmation, it again implies
that the health benefits may not be constant over time
and could increase—which would make the device
more attractive from a purely economic perspective.
We are concerned that the majority of our clinic at-
tenders were unable to complete the time trade-off val-
uations, even in the presence of a research nurse (SM).
Nonetheless, the minority who completed the valua-
tions produced results consistent with Messori et al.15.
The values from the EQ-5D instrument are arguably
more robust, but were associated with a higher ratio
of cost to quality adjusted life years gained (£49 233).
The model was relatively insensitive to changes in
length of stay or complication rates, as an increase in
the complication rate to 10% had very little impact
on the final cost per quality adjusted life year ratio.
Accordingly, there is not a strong economic imperative
to perform implantation as a daycase.
If it is possible to identify and implant a group with a
high response rate extremely favourable cost per qual-
ity adjusted life year values are obtained (£4785 per
QALY, if one out of every three people implanted are
responders). One follow-up study reported a absolute
reduction in seizure frequency of 28–33%23, which
would translate into numbers needed to treat of two
or three per successful implant.
If the battery life of a vagus nerve stimulator was
extended to 6 years instead of 5, the baseline cost
per quality adjusted life year gained falls further (to
£24 000). While it is possible to estimate cost per
quality adjusted life year gained over a longer period
of time, there is insufficient data to accurately model
device prognosis or device efficacy beyond the cur-
rent expected battery life span of 5 years. Nonethe-
less, it is important to keep the time horizon short as
the introduction of a novel, more effective treatment
for refractory epilepsy could be introduced in the near
future, which would seriously undermine the conclu-
sions of an economic model based upon a prolonged
time of treatment. We would anticipate that cost per
quality adjusted life year estimates from a 10 year
model would be extremely favourable.
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Before recommending investment in VNS devices
in a resource constrained health care system, there re-
mains the more fundamental consideration of efficacy.
Arguably all people with epilepsy want seizure free-
dom, not partial relief (i.e. a 50% reduction in seizure
frequency). Although seizure freedom is rare follow-
ing VNS, our seven time trade-off respondents placed
a very high value upon a 50% reduction in seizure fre-
quency. These respondents valued a life expectancy of
20 years with their current epilepsy severity as of the
same value as 14.3 years of epilepsy with a 50% reduc-
tion in seizure frequency. This undermines a widely
held view that a 50% reduction in seizure frequency is
of little value, and implies that a successful VNS has
a clinically meaningful impact from the perspective of
a person with medically refractory epilepsy.
An economic argument against VNS would be ten-
able if competing treatments for other people with
epilepsy had a far smaller cost per quality adjusted
life year gained. According to quality adjusted life
year theory, the intervention with the lowest cost per
quality adjusted life year gained is the intervention
that will produce greatest health for a target popu-
lation for a given amount of resource24. A success-
ful VNS implant is of comparable efficacy to add-on
anti-convulsants, i.e. for every six people treated you
will get at least one good response25. Compared to
add-on anti-convulsants, VNS has a favourable eco-
nomic status, e.g. Lamotrigine add-on therapy26 at
£33 339 per quality adjusted life years gained (pub-
lished as US$43 343 in 1990 values, inflated to 1996
prices and converted to £ using purchasing power par-
ity factor of 0.64114). Compared to our baseline value
of £28 849, VNS for medically refractory epilepsy has
a more favourable cost per quality adjusted life year
gained, yet the argument for VNS becomes more com-
pelling as VNS is a final option, not one of a host of
add-on therapies. Studies of anterior temporal lobec-
tomy for epilepsy have estimated the cost per quality
adjusted life year gained as £10 27727 (published as
US$15 581 in 1995 prices), and £18 46328 (published
as US$27 200 in 1994 prices). These values for an-
terior lobectomy are broadly comparable to the more
favourable estimates presented for VNS in this paper.
The decision to invest in a novel health technology
may depend on clinical factors such as the absence of
alternative treatments but may equally depend upon
political imperatives. Definitions of good and bad
value for money have not been accurately defined.
Nonetheless, cut off values of £10 000 per quality
adjusted life year gained have been set as a threshold
below which an intervention would represent efficient
use of scarce resources29. Arguably, interventions
above £30 000 per quality adjusted life year gained
should have their implementation deferred until costs
fall or political imperatives prevail30. If a new technol-
ogy produces very small gains in health at a very high
cost, there is an economic argument for not investing
in that technology and considering alternatives, as
these alternatives may produce greater benefits to a
greater number of people31. Alternatively, if a new
technology provided meaningful health gains at a rea-
sonably low cost there would not be a strong economic
argument against investing in the new technology24. In
the case of VNS, the initial expense is ultimately off-
set by costs averted from improved epilepsy control,
and most of our cost-utility estimates are within an ac-
ceptable range. The possibility of a meaningful reduc-
tion in seizure frequency for people with intractable
epilepsy is very hard for patients or neurologists to
resist—irrespective of the conclusions of an economic
evaluation—but this economic information is de-
manded by purchasers in modern healthcare systems.
Vagus nerve stimulator devices have become an ac-
ceptable treatment for epilepsy. Our economic model
demonstrates that the economic argument against a
programme of implantation is weak, and therefore the
decision to implant should be primarily on clinical and
efficacy grounds.
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